HTR1A and schizophrenia: The serotonin receptor subtype 5-HT1A has been implicated in several neurological conditions, and 5-HT1A receptor agonism represents efficacious therapeutic potential for the treatment of major depression, anxiety, schizophrenia, and Parkinson’s disease.